148 related articles for article (PubMed ID: 36930525)
1. The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine.
Machens A; Lorenz K; Brandenburg T; Führer-Sakel D; Weber F; Dralle H
J Clin Endocrinol Metab; 2023 Aug; 108(9):e734-e742. PubMed ID: 36930525
[TBL] [Abstract][Full Text] [Related]
2. Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.
Wang YP; Li FP; Wang HH; Fang XD; Zhu ZS; Chen YL; Qi XP
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):339-347. PubMed ID: 34445950
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in MEN 2A penetrance and expression according to parental inheritance.
Machens A; Lorenz K; Weber F; Dralle H
Eur J Endocrinol; 2022 Feb; 186(4):469-476. PubMed ID: 35130180
[TBL] [Abstract][Full Text] [Related]
5. 100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.
Machens A; Elwerr M; Lorenz K; Weber F; Dralle H
Endocrine; 2020 May; 68(2):368-376. PubMed ID: 32100189
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation of MEN 2A in index vs. non-index patients.
Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H
Endocrine; 2023 Nov; 82(2):450-455. PubMed ID: 37477781
[TBL] [Abstract][Full Text] [Related]
7. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
[TBL] [Abstract][Full Text] [Related]
8. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 2.
Gertner ME; Kebebew E
Curr Treat Options Oncol; 2004 Aug; 5(4):315-25. PubMed ID: 15233908
[TBL] [Abstract][Full Text] [Related]
10. Elevated basal serum levels of calcitonin and simultaneous surgery of MEN2A-specific tumors.
Tang HX; Yang H; Li F; Cao ZL; Huang YT; Qi XP
Neoplasma; 2021 Sep; 68(5):1098-1106. PubMed ID: 34156257
[TBL] [Abstract][Full Text] [Related]
11. [A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
Weng Y; Xue SN; Zhang SL; Cheng H; Yan L
Zhonghua Nei Ke Za Zhi; 2018 Feb; 57(2):134-137. PubMed ID: 29397600
[TBL] [Abstract][Full Text] [Related]
12. Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2.
Tavares MR; Toledo SP; Montenegro FL; Moyses RA; Toledo RA; Sekyia T; Cernea CR; Brandão LG
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):149-54. PubMed ID: 22584721
[TBL] [Abstract][Full Text] [Related]
13. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2013 Feb; 98(2):E336-45. PubMed ID: 23284010
[TBL] [Abstract][Full Text] [Related]
14. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A.
Machens A; Dralle H
J Clin Endocrinol Metab; 2015 Jul; 100(7):2539-45. PubMed ID: 25946031
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case.
Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Uchino S; Kosugi S; Kurahashi H; Iwase K
Surg Today; 2014 Nov; 44(11):2195-200. PubMed ID: 24449023
[TBL] [Abstract][Full Text] [Related]
17. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
[TBL] [Abstract][Full Text] [Related]
18. Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome.
Lendvai N; Tóth M; Valkusz Z; Bekő G; Szücs N; Csajbók E; Igaz P; Kriszt B; Kovács B; Rácz K; Patócs A
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):85-9. PubMed ID: 22584711
[TBL] [Abstract][Full Text] [Related]
19. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
Mian C; Barollo S; Zambonin L; Pennelli G; Bernante P; Pelizzo MR; Nacamulli D; Mantero F; Girelli ME; Opocher G
Fam Cancer; 2009; 8(4):379-82. PubMed ID: 19475497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
